Rafferty Asset Management, LLC Viking Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 253,753 shares of VKTX stock, worth $10.7 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

253,753

Previous 335,566 24.38%

Holding current value

$10.7 Million

Previous $17.8 Million 9.69%

% of portfolio

0.06%

Previous 0.07%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$49.84 - $70.47 $4.08 Million - $5.77 Million	-81,813 Reduced 24.38%	253,753 $16.1 Million
Q2 2024 Aug 13, 2024	BUY	$47.39 - $80.2 $9.85 Million - $16.7 Million	207,810 Added 162.66%	335,566 $17.8 Million
Q1 2024 May 13, 2024	SELL	$17.4 - $94.5 $4.97 Million - $27 Million	-285,522 Reduced 69.09%	127,756 $10.5 Million
Q4 2023 Feb 13, 2024	SELL	$9.24 - $19.64 $1.36 Million - $2.89 Million	-146,902 Reduced 26.22%	413,278 $7.69 Million
Q3 2023 Nov 13, 2023	BUY	$10.92 - $16.0 $2.38 Million - $3.49 Million	217,827 Added 63.63%	560,180 $6.2 Million
Q2 2023 Aug 11, 2023	SELL	$14.84 - $24.79 $2.94 Million - $4.91 Million	-197,959 Reduced 36.64%	342,353 $5.55 Million
Q1 2023 May 11, 2023	BUY	$8.08 - $17.33 $4.37 Million - $9.36 Million	540,312 New	540,312 $9 Million
Q1 2022 May 13, 2022	SELL	$3.0 - $4.88 $687,357 - $1.12 Million	-229,119 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$4.6 - $6.72 $449,488 - $656,644	97,715 Added 74.36%	229,119 $1.05 Million
Q3 2021 Nov 10, 2021	SELL	$5.58 - $7.04 $301,498 - $380,385	-54,032 Reduced 29.14%	131,404 $825,000
Q2 2021 Aug 10, 2021	SELL	$5.19 - $6.73 $843,551 - $1.09 Million	-162,534 Reduced 46.71%	185,436 $1.11 Million
Q1 2021 May 10, 2021	BUY	$5.74 - $9.67 $1.68 Million - $2.82 Million	291,934 Added 520.98%	347,970 $2.2 Million
Q4 2020 Feb 10, 2021	SELL	$5.3 - $6.71 $512,001 - $648,212	-96,604 Reduced 63.29%	56,036 $315,000
Q3 2020 Nov 13, 2020	BUY	$5.73 - $8.11 $573,888 - $812,257	100,155 Added 190.83%	152,640 $888,000
Q2 2020 Aug 07, 2020	BUY	$4.35 - $8.08 $165,961 - $308,268	38,152 Added 266.18%	52,485 $378,000
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $370,578 - $853,941	-107,414 Reduced 88.23%	14,333 $67,000
Q4 2019 Feb 10, 2020	SELL	$6.38 - $8.73 $863,169 - $1.18 Million	-135,293 Reduced 52.63%	121,747 $976,000
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $1.48 Million - $1.94 Million	-226,052 Reduced 46.79%	257,040 $1.77 Million
Q2 2019 Aug 09, 2019	BUY	$7.67 - $10.63 $287,801 - $398,869	37,523 Added 8.42%	483,092 $4.01 Million
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $3.38 Million - $4.43 Million	445,569 New	445,569 $4.43 Million

Others Institutions Holding VKTX

# of Institutions

473

Shares Held

65.6M

Call Options Held

5.72M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Viking Therapeutics, Inc. Transaction History